Radiographic Bone Evaluation after Periodontal Full Mouth Disinfection Treatment in Women Undergoing Chemotherapy or Hormone Therapy with Tamoxifen

Rahyza Inácio Freire de Assis, Manoelito Ferreira Silva Junior, Marciel Silva Santos, Teresa Cristina Rangel Pereira, Alfredo Carlos Ribeiro Feitosa, Sérgio Lins de Azevedo-Vaz

Abstract


Objective: To radiographically evaluate the alveolar bone level after periodontal full mouth disinfection (FMD) treatment in women during chemotherapy (CHE) and hormone therapy with Tamoxifen (TAM). Material and Methods: This is an uncontrolled clinical trial with a convenience sample of women in antineoplastic treatment (CHE and TAM) and non-surgical periodontal FMD treatment. The Radiographic examination consisted of four bitewing radiographs and six periapical radiographs of the upper and lower anterior teeth, acquired according to the parallelling standard technique at three times: before (T0), 3 (T3) and 6 (T6) months after periodontal treatment. The alveolar crest level in the interproximal area of each tooth was measured by two calibrated observer using magnifying glass and digital caliper. Statistical analysis was performed for evaluation of the three times in each experimental group using the Friedman test (p < 0.05) and between groups, the Mann Whitney test (p <0.05). Results: Overall, 14 women undergoing treatment for breast cancer participated in this study. A follow-up loss of five (35.71%) women occurred during the study and the final sample size was composed of nine women divided into two groups: CHE (n = 4) and TAM (n = 5). A total of 330 sites were evaluated: 126 (CHE) and 204 (TAM). The alveolar bone level showed statistically significant reduction after 6 months of FMD therapy (p <0.05), but there was no difference between antineoplastic treatment type (p> 0.05). Conclusion: Patients undergoing chemotherapy and hormone therapy with Tamoxifen showed better alveolar bone levels after six months of periodontal FMD treatment. The current antineoplasic therapy did not influence the results obtained with periodontal treatment.

Keywords


Breast cancer; Chemotherapy; Tamoxifen; Dental Radiography

Full Text:

PDF

References


Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature 2008; 454(7203):436-44.

Reynolds MA. Modifiable risk factors in periodontitis: at the intersection of aging and disease. Periodontology 2000 2014; 64(1):7-19.

Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76.

Igene H. Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J 2008; 14:428-34.

Gonzalez-Ângulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Advances in experimental medicine and biology 2007; 608:1-22.

Saad ED, Bromberg S, Katz A, Simon SD. Inibidores da aromatase no câncer de mama: da doença metastática ao tratamento adjuvante. Rev Bras Cancerol 2002; 48:555-67.

Leal JH, Cubero D, Giglio AD. Hormonioterapia paliativa em câncer de mama: aspectos práticos e revisão da literatura. Rev Bras Clin Med 2010; 8:338-43.

Taichman LS, Havens AM, Poznak CHV. Potential implications of adjuvante endocrine therapy for the oral health of postmenopausal women with breast cancer. Breast Cancer Res Treat 2013; 137:23-32.

Khan MN, Khan AA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol 2008; 15 (Suppl 1): 30-40.

Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011; 22:2546-55.

Oringer RJ. Research, Science, Therapy Committee of the American Academy of Periodontology. Modulation of the host response in periodontal therapy. J Periodontol 2002; 3:460-70.

Ryan ME. Nonsurgical approaches for the treatment of periodontal diseases. Dent Clinics North Am 2005; 49:611-36.

Fang H, Han M, Li QL, Cao CY, Xia R, Zhang ZH. Comparison of full-mouth disinfection and quadrant-wise scaling in the treatment of adult chronic periodontitis: a systematic review and meta-analysis. J Periodont Res 2015; 51(4):417-30.

Quirynen M, Bollen C, Vandekerckhove B, Dekeyser C, Papaioannou W, Eyssen H. Full-vs. partial-mouth disinfection in the treatment of periodontal infections: short- term clinical and microbiological observations. J Dent Res 1995; 74:1459-67.

Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-74.

Bahrami G, Isidor F, Kirkevang LL, Vaeth M, Wenzel A. Marginal bone level in an adult Danish Population. Oral Health Prev Dent 2006; 4:119-27.

Vandenberghe B, Bosmans H, Yang J, Jacobs R. A comprehensive in vitro study of image accuracy and quality for periodontal diagnosis. Part 2: The influence of intra-oral image receptor on periodontal measurements. Clin Oral Investig 2011; 15:551-62.

Szklo R, Nieto FJ. Epidemiology Beyond the Basics. 3 ed. Burlington: Jones & Bartlett Learning; 2012.

Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. J Dent Res 2014; 93:1045-53.

Offenbacher S, Page RC, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1997; 14:216-48.

Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005; 366:1809-20.

Perry DA, Takei HH. Fase I da terapia periodontal. In: Newman MG, Takei HH, Klokkevold PR, Carranza FA. Periodontia Clínica. 10. ed. Rio de Janeiro: Elsevier, 2012. p. 518-522.

Lindhe J, Westfelt E, Nyman S, Socransky SS, Haffajee AD. Long-term effect of surgical/non-surgical treatment of periodontal disease. J Clin Periodontol 1984: 11;448-58.

Ramfjord SP, Caffesse RG, Morrison EC. 4 modalities of periodontal treatment compared over 5 years. J Clin Periodontol 1987; 14:445-52.

Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013; 9:365-74.

Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26:1051-8.

Giacomini DR, Mella EAC. Reposição Hormonal: vantagens e desvantagens. Semina Cienc Biol Saude 2006; 27:71-92.

Fewtrell MS, Kennedy K, Singhal A, Martin RM, Ness A, Hadders-Algra M, Koletzko B, Lucas A. How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? Arch Dis Child 2008; 93:458-61.




PBOCI IS A MEMBER OF CROSSREF AND ALL THE CONTENT OF ITS JOURNALS ARE LINKED BY DOIS THROUGH CROSSREF.